Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in HIF-1-active tumor cells

Journal of Nuclear Medicine

Volumn 50, Issue 6, 2009, Pages 942-949

  Kudo, Takashi ^a   Ueda, Masashi ^a,b   Kuge, Yuji ^a   Mukai, Takahiro ^c   Tanaka, Shotaro ^d   Masutani, Maki ^a   Kiyono, Yasushi ^b,e   Kizaka Kondoh, Shinae ^d   Hiraoka, Masahiro ^d   Saji, Hideo ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e UNIVERSITY OF FUKUI   (Japan)

Author keywords

Hypoxia inducible factor 1 (HIF 1); Molecular imaging; Oncology; Oxygen dependent degradation (ODD); Protein transduction domain (PTD); Radiopharmaceuticals; Tumor hypoxia

Indexed keywords

(3 IODOBENZOYL)NORBIOTINAMIDE I 123; (3 IODOBENZOYL)NORBIOTINAMIDE I 125; AMIDE; BIOTIN DERIVATIVE; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR 1 ALPHA OXYGEN DEPENDENT DEGRADATION DOMAIN PROTEIN TRANSDUCTION DOMAIN STREPTAVIDIN (3 IODOBENZOYL)NORBIOTINAMIDE I 123; HYPOXIA INDUCIBLE FACTOR 1 ALPHA OXYGEN DEPENDENT DEGRADATION DOMAIN PROTEIN TRANSDUCTION DOMAIN STREPTAVIDIN (3 IODOBENZOYL)NORBIOTINAMIDE I 125; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IODINE 123; IODINE 125; LUCIFERIN; OXYGEN; PIMONIDAZOLE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CELL ASSAY; CELL CULTURE; CELL STRAIN; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG SYNTHESIS; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; MOLECULAR PROBE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; RADIOASSAY; RADIOSENSITIVITY; TUMOR HYPOXIA;

ANIMALS; BIOTIN; CELL HYPOXIA; CELLS, CULTURED; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IODINE RADIOISOTOPES; MICE; MICE, INBRED C3H; NEOPLASMS; RADIOPHARMACEUTICALS; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION;

EID: 66649093239     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.108.061119     Document Type: Article

References (34)

1. Vaupel P, Kallinowski F, Okunieff P. Blood-flow, oxygen and nutrient supply, and metabolic microenvironment of human-tumors: a review. Cancer Res. 1989;49:6449-6465. (Pubitemid 20008770)
2. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today. 2000;6:157-162. (Pubitemid 30171366)
3. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266-276. (Pubitemid 32219813)
4. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev. 1994;13:139-168.
5. Semenza GL. Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol. 2000;59:47-53.
6. 2- regulated gene expression. FASEB J. 2002;16:1151-1162.
7. Harada H, Kizaka-Kondoh S, Li G, et al. Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene. 2007;26:7508-7516. (Pubitemid 350207705)
8. Marignol L, Coffey M, Lawler M, Hollywood D. Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev. 2008;34:313-327.
9. Miyake K, Yoshizumi T, Imura S, et al. Expression of hypoxia-inducible factor-1a, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation. Pancreas. 2008;36:e1-e9.
10. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294:1337-1340. (Pubitemid 33063099)
11. 2 tension. Proc Natl Acad Sci USA. 1995;92:5510-5514.
12. Harada H, Kizaka-Kondoh S, Hiraoka M. Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging. 2005;4:182-193. (Pubitemid 43143791)
13. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: a target for selective cancer therapy. Cancer Sci. 2003;94:1021-1028. (Pubitemid 38035514)
14. Harada H, Hiraoka M, Kizaka-Kondoh S. Antitumor effect of TAT-oxygen-dependent degradation-caspase-3 fusion protein specifically stabilized and activated in hypoxic tumor cells. Cancer Res. 2002;62:2013-2018. (Pubitemid 34408445)
15. Kageyama Y, Sugiyama H, Ayame H, et al. Suppression of VEGF transcription in renal cell carcinoma cells by pyrrole-imidazole hairpin polyamides targeting the hypoxia responsive element. Acta Oncol. 2006;45:317-324. (Pubitemid 43675573)
16. Inoue M, Mukai M, Hamanaka Y, Tatsuta M, Hiraoka M, Kizaka-Kondoh S. Targeting hypoxic cancer cells with a protein prodrug is effective in experimental malignant ascites. Int J Oncol. 2004;25:713-720.
17. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999;285:1569-1572.
18. Harada H, Kizaka-Kondoh S, Hiraoka M. Mechanism of hypoxia-specific cytotoxicity of procaspase-3 fused with a VHL-mediated protein destruction motif of HIF-1α containing Pro564. FEBS Lett. 2006;580:5718-5722. (Pubitemid 44498671)
19. Kizaka-Kondoh S, Itasaka S, Zeng L, et al. Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res. In press.
20. Foulon CF, Alston KL, Zalutsky MR. Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and ((5-iodo-3-pyridinyl)carbonyl) norbiotinamide: two radioiodinated biotin conjugates with improved stability. Bioconjug Chem. 1997;8:179-186. (Pubitemid 27153291)
21. Ishino S, Kuge Y, Takai N, et al. 99mTc-annexin A5 for noninvasive characterization of atherosclerotic lesions: imaging and histological studies in myocardial infarction-prone Watanabe heritable hyperlipidemic rabbits. Eur J Nucl Med Mol Imaging. 2007;34:889-899. (Pubitemid 46798948)
22. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008;49(suppl 2):129S-148S.
23. Rasey JS, Nelson NJ, Chin L, Evans ML, Grunbaum Z. Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res. 1990;122:301-308. (Pubitemid 20214420)
24. 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med. 1999;40:177-183.
25. Vavere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans. 2007;4893-4902. (Pubitemid 350015414)
26. Sobhanifar S, Aquino-Parsons C, Stanbridge EJ, Olive P. Reduced expression of hypoxia-inducible factor-1α in perinecrotic regions of solid tumors. Cancer Res. 2005;65:7259-7266. (Pubitemid 41161257)
27. Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am J Physiol. 1996;271:C1172-C1180. (Pubitemid 126757715)
28. Chauhan A, Tikoo A, Kapur AK, Singh M. The taming of the cell penetrating domain of the HIV Tat: myths and realities. J Control Release. 2007;117:148-162. (Pubitemid 46172502)
29. Paltoglou S, Roberts BJ. HIF-1α and EPAS ubiquitination mediated by the VHL tumour suppressor involves flexibility in the ubiquitination mechanism, similar to other RING E3 ligases. Oncogene. 2007;26:604-609. (Pubitemid 46160973)
30. Ebner A, Marek M, Kaiser K, et al. Application of biotin-4-fluorescein in homogeneous fluorescence assays for avidin, streptavidin, and biotin or biotin derivatives. Methods Mol Biol. 2008;418:73-88.
31. Zhu W, Okollie B, Bhujwalla ZM, Artemov D. PAMAM dendrimer-based contrast agents for MR imaging of Her-2/neu receptors by a three-step pretargeting approach. Magn Reson Med. 2008;59:679-685.
32. Forster GJ, Santos EB, Smith-Jones PM, Zanzonico P, Larson SM. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J Nucl Med. 2006;47:140-149. (Pubitemid 46768523)
33. Safran M, Kim WY, O'Connell F, et al. Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. Proc Natl Acad Sci USA. 2006;103:105-110. (Pubitemid 43076112)
34. Trastour C, Benizri E, Ettore F, et al. HIF-1α and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer. 2007;120:1451-1458. (Pubitemid 46355379)